Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0028754 (
obesity
)
124,988
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Regulation of energy metabolism is critical for the prevention of
obesity
, diabetes, and hepatic steatosis. Here, we report an important role for the pleckstrin homology-related domain family member,
T-cell death-associated gene 51
(
TDAG51
), in the regulation of energy metabolism.
TDAG51
expression was examined during adipocyte differentiation. Adipogenic potential of preadipocytes with knockdown or absence of
TDAG51
was assessed. Weight gain, insulin sensitivity, metabolic rate, and liver lipid content were also compared between
TDAG51
-deficient (
TDAG51
(-/-)) and wild-type mice. In addition to its relatively high expression in liver,
TDAG51
was also present in white adipose tissue (WAT).
TDAG51
was downregulated during adipogenesis, and
TDAG51
(-/-) preadipocytes exhibited greater lipogenic potential.
TDAG51
(-/-) mice fed a chow diet exhibited greater body and WAT mass, had reduced energy expenditure, displayed mature-onset insulin resistance (IR), and were predisposed to hepatic steatosis.
TDAG51
(-/-) mice had increased hepatic triglycerides and SREBP-1 target gene expression. Furthermore,
TDAG51
expression was inversely correlated with fatty liver in multiple mouse models of hepatic steatosis. Taken together, our findings suggest that
TDAG51
is involved in energy homeostasis at least in part by regulating lipogenesis in liver and WAT, and hence, may constitute a novel therapeutic target for the treatment of
obesity
and IR.
...
PMID:Loss of TDAG51 results in mature-onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis. 2296 Oct 87